Table 1. Characteristics of included studies.
| First author | Year | Region | Sample | Measure method | Age (years) | N. of M/F | Primary antibody | Treatment | Follow-up |
|---|---|---|---|---|---|---|---|---|---|
| Bian | 2015 | China | Tissue | IHC | NR | NR | Rabbit Ab | Surgery | Median 49 months |
| (2-80months) | |||||||||
| Chang | 2015 | Korea | Tissue | IHC | Mean 58.1 | 285/139 | Rabbit pAb | Surgery | Mean 82.3 months; |
| Median 61 | Median96.1months | ||||||||
| (1 –131 months) | |||||||||
| Cinti | 2008 | Italy | Tissue | IHC | 34-83years | 16/34 | mAb | Surgery | at least 5 years |
| Han | 2011 | China | Tissue | IHC | Median 53 | 85/23 | Rabbit pAb | Surgery | About 5 years |
| Chemotherapy | |||||||||
| Kobayashia | 2006 | Japan | Tissue | IHC | NR | NR | Rabbit pAb | Surgery | >40 months |
| Liang | 2015 | China | Tissue | IHC | NR | NR | mAb | Surgery | >5 years |
| Luber | 2011 | Europe | Tissue | IHC | Median 63 | 30/9 | Mouse mAb | Chemotherapy | Median 379 days |
| Murakami | 2007 | Japan | Tissue | IHC | Mean 70.8 | 84/56 | Mouse pAb | Surgery | at least 5 years |
| Chemotherapy | |||||||||
| Murayama | 2009 | Japan | Tissue | IHC | Median 65 | 77/32 | Rabbit pAb | Surgery | Median 1953 days |
| (50– 3197 days) | |||||||||
| Nam | 2003 | Korea | Tissue | IHC | Mean 54.8 | 210/101 | NR | Surgery | Mean 54 months |
| (1-72 months) | |||||||||
| Sasaki | 2014 | Japan | Tissue | Immunoblot | NR | NR | NR | Surgery | >5 years |
| Sukawa | 2012 | Japan | Tissue | IHC | Median 71 | 157/74 | pAb | Surgery | About 10 years |
| Xue | 2012 | China | Tissue | IHC | Median65.5 | 158/71 | Mouse pAb | Surgery | >5 years |
N. of P.: the number of patients; M/F: male/female; mAb: monoclonal antibody; pAb: polyclonal antibody; NR: not reported.